United States of America

Using CSF biomarkers to link pathology and clinical presentation

May 18, 2022

In this article series we aim at highlighting the current state of knowledge and the latest developments in the field of Alzheimer’s disease (AD) testing. This chapter looks at neurodegenerative biomarker changes in cerebrospinal fluid.

Other articles in this series:

 
The cerebrospinal fluid (CSF) is the optimal source for biomarkers to establish ante-mortem a link between clinical features and underlying pathologic features.

Brain neurodegenerative diseases (NDD) are commonly classified by distinct clinical presentations, e.g., impairment in cognitive functioning involving anatomical regions showing neuronal dysfunction and loss. Most of these diseases follow a deteriorating course to dementia. Fifty to seventy-five percent of dementia cases are due to Alzheimer’s pathology.

Most cases of disease are sporadic, but some are inherited in a dominant manner. In these cases, the overexpression of mutant proteins rises to disease-associated phenotypes with early occurrence of disease often.

 
Most frequent neurodegenerative dementias

Most frequent neurodegenerative dementias

 
For some diseases, only the criteria referring to the clinical phenotype are used for subtyping, whereas for others biochemical modifications or gene polymorphisms could also to be considered. The classification gains in confidence based on positive evidence of the presence of pathological protein deposits in brain.

The accumulation of brain pathologies seems to be a nearly inevitable consequence of aging; there is frequently an overlap of concomitant pathologies.

Subscribe to Fujirebio insight updates

Get all the latest insight articles from Fujirebio the moment they are published.

CAPTCHA

The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

How well do the CSF biomarkers perform diagnostically?

Although a multitude of CSF biomarkers for specific pathologic changes and nonspecific markers of oxidative damage or inflammation involved in neurodegenerative diseases were studied, only three core biomarkers are validated for a differential diagnosis of AD, i.e. Aβ1-42 peptide (Aβ42), total tau (T-tau), and its phosphorylated form (P-tau) measured in vitro using CSF specimens.

CSF α-syn is currently studied for its possible value as a PD biomarker and in the differential diagnosis of NDD, but not validated. Current commercial assays detecting total α-syn levels seem not able to distinguish Lewy body disorders from other neurodegenerative disorders.

The detection of CSF PrPSc is performed only in reference laboratories for prion diseases with the nonspecific 14-3-3 protein. For now, only results of CSF Aβ42 (or CSF Aβ42/40 ratio), T-tau and P-tau can be used in routine clinical setting.

Overview of clinical effectiveness of established Alzheimer’s disease biomarkers

Overview of clinical effectiveness of established Alzheimer’s disease biomarkers

 
The concomitant pathologies in elderly individuals lead to an artificial clinical subgrouping driven by the dominant clinical phenotype. The common age-associated brain pathologies are amyloid plaques, tangles, ischemic cerebrovascular disease but also microinfarctions, hippocampal sclerosis, α-syn deposits (Lewy bodies), TDP43 inclusions, and argyrophilic grains.

A clinical phenotype (typical, atypical or unclear) and the CSF core biomarkers reflecting the dynamic changes of protein metabolism in the brain help in differentiating pathological neurodegenerative decline from normal aging.

Change of specific biomarkers for Alzheimer’s disease in other dementias

Change of specific biomarkers for Alzheimer’s disease in other dementias

Bibliography

  • Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Dubois B, et al. Lancet Neurol. 2021; 20(6): 484-496. Review.
  • Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Simonsen AH, et al. Alzheimers Dement. 2017; 13(3): 274-284. Review.
  • Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Blennow K, et al. Alzheimers Dement. 2015; 11(1): 58-69. Review.
  • Biomarker modeling of Alzheimer’s disease. Jack CR Jr, et al. Neuron. 2013; 80(6): 1347-1358. Review.
  • Fluid biomarkers in Alzheimer’s disease - current concepts. Rosén C, et al. Mol Neurodegener. 2013; 8: 20. Review

Related articles

Related products

INNOTEST® hTAU Ag

CE marked (IVDR)
81572, 81573
View product

INNOTEST® hTAU Ag

For research use only
81579
View product

INNOTEST® NPTX2

For research use only
80908, 80909
View product

INNOTEST® PHOSPHO-TAU(181P)

CE marked (IVDR)
81574
View product

INNOTEST® sTREM2

For research use only
81056, 81057
View product

INNOTEST® β-AMYLOID(1-42)

CE marked (IVDR)
81576
View product

Lumipulse® G ApoE4

For research use only
81453, 81454
View product
Lumipulse G pTau 181 Immunoreaction Cartridges (230350) and Lumipulse G pTau 181 Calibrators set (230367)

Lumipulse® G pTau 181

CE marked
230350, 230367
View product
Lumipulse G Total Tau

Lumipulse® G Total Tau

CE marked
230312, 230329
View product
Lumipulse G β-Amyloid 1-40 Immunoreaction Cartridges (231524) and Lumipulse G β-Amyloid 1-40 Calibrators (231531)

Lumipulse® G β-Amyloid 1-40

CE marked
231524, 231531
View product
Lumipulse G β-Amyloid 1-42 Immunoreaction Cartridges (230336) and Lumipulse G β-Amyloid 1-42 Calibrators (230343)

Lumipulse® G β-Amyloid 1-42

CE marked
230336, 230343
View product

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.
site by D'M&S